Related Experiment Video

Updated: May 10, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Overview of the latest treatments for castration-resistant prostate cancer

Mohamed Bishr1, Fred Saad

  • 1Centre de Recherche, Centre Hospitalier de l'Université de Montréal, 1560 Sherbrooke East, Montréal, QC H2L 4M1, Canada.

Nature Reviews. Urology
|June 26, 2013
PubMed

Insights

Recent advances offer new treatments for advanced prostate cancer. New therapies like abiraterone acetate and radium-223 improve survival for castration-resistant prostate cancer patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Prostate cancer progression and castration resistance are driven by complex molecular mechanisms.
  • Therapeutic options for castration-resistant prostate cancer (CRPC) have significantly expanded.
  • Understanding these mechanisms is crucial for developing effective treatments.

Purpose of the Study:

  • To review the recent advancements in understanding prostate cancer progression and castration resistance.
  • To summarize the new therapeutic agents available for castration-resistant prostate cancer (CRPC).
  • To highlight the role of androgen receptor pathway targeting and bone-targeted therapies.

Main Methods:

  • Review of recent clinical trial data and scientific literature.
  • Analysis of the efficacy of novel therapeutic agents in CRPC.
  • Evaluation of molecular mechanisms underlying CRPC development.

Main Results:

  • Four new agents (cabazitaxel, abiraterone acetate, enzalutamide, radium-223) prolong overall survival in CRPC patients.
  • Abiraterone acetate and enzalutamide show significant promise in targeting the androgen receptor pathway.
  • Cabazitaxel is the standard second-line chemotherapy for metastatic CRPC (mCRPC).
  • Denosumab delays bone metastases, and radium-223 improves survival in mCRPC.

Conclusions:

  • Targeting the androgen receptor pathway remains a key strategy in CRPC treatment.
  • New bone-targeted therapies and radiopharmaceuticals offer improved outcomes for CRPC patients.
  • Continued research into molecular mechanisms will drive further therapeutic innovation for advanced prostate cancer.

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...